Juvenile nasopharyngeal angiofibroma: a single centre's 11-year experience.

Juvenile nasopharyngeal angiofibroma: a single centre's 11-year experience.

J Laryngol Otol. 2018 Oct 22;:1-6

Authors: Pamuk AE, Özer S, Süslü AE, Akgöz A, Önerci M

Abstract
OBJECTIVE: This study aimed to present the clinical features and surgical outcomes of juvenile nasopharyngeal angiofibroma patients who were surgically treated.
METHODS: The medical records of 48 male patients histologically confirmed as having juvenile nasopharyngeal angiofibroma, who underwent transnasal endoscopic surgery between 2005 and 2016, were retrospectively reviewed.
RESULTS: The overall recurrence rate was 20.8 per cent; however, the recurrence rate differed significantly between patients diagnosed aged less than 14 years (34.7 per cent) and more than 14 years (8 per cent) (p < 0.05). Advanced-stage tumours (Radkowski stage of IIC or more, and Önerci stage of III or more) were more aggressive than earlier stage tumours (p < 0.05 and p < 0.01, respectively). Pre-operative embolisation significantly prolonged mean hospitalisation duration, but had no effect on intra-operative blood loss in patients with advanced-stage tumours (p < 0.001 and p = 0.09, respectively).
CONCLUSION: The findings show that transnasal endoscopic surgery could be considered the treatment of choice for juvenile nasopharyngeal angiofibroma. Patients diagnosed when aged less than 14 years and those with advanced-stage tumours are at risk of recurrence, and should be monitored with extreme care.

PMID: 30345941 [PubMed - as supplied by publisher]

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2D0rhhA